OBD vs. SAR, POLB, COS, C4XD, DDDD, APTA, FUM, AREC, OKYO, and AOR
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Sareum (SAR), Poolbeg Pharma (POLB), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Aptamer Group (APTA), Futura Medical (FUM), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs. Its Competitors
Oxford BioDynamics (LON:OBD) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.
In the previous week, Sareum had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Oxford BioDynamics. Sareum's average media sentiment score of 0.67 beat Oxford BioDynamics' score of 0.00 indicating that Sareum is being referred to more favorably in the news media.
11.4% of Oxford BioDynamics shares are held by institutional investors. 15.5% of Oxford BioDynamics shares are held by insiders. Comparatively, 36.6% of Sareum shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, indicating that its share price is 208% less volatile than the S&P 500.
Sareum has lower revenue, but higher earnings than Oxford BioDynamics. Sareum is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
Sareum has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,800.32%. Sareum's return on equity of -270.25% beat Oxford BioDynamics' return on equity.
Summary
Sareum beats Oxford BioDynamics on 7 of the 12 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 9/24/2025 by MarketBeat.com Staff
Free OBD Stock Alerts